* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Progenics Pharmaceuticals

                   

Solid Tumor Space Companies Examined in Wall Street Transcript Biotechnology Report (Wall Street...

yahoo.com
Jun 27, 2008 3 related
        

67 WALL STREET, New York - The Wall Street Transcript has just published its Biotechnology issue, a report offering a timely review of the sector to serious investors and industry executives. The full issue is available by...

add comment

TradingMarkets Monday Stock Movers: AVNX, CHRD, PGNX, SCUR, WNR (TradingMarkets.com)

yahoo.com
Jun 2, 2008
        

With the markets opening lower, there are a number of weak stocks that had been drifting higher in recent days, becoming more and more overbought in the process. Here are 5 stocks with low Short Term PowerRatings that may be in the...

add comment
                   

New drug may ease severe constipation

msn.com
May 29, 2008 9 related
        

An experimental once-a-day pill offered relief to nearly half the people with severe, long-term constipation, researchers reported on Wednesday. ... Once-a-day pill helps people with long-term condition, researchers report BOSTON - The drug prucalopride, which...

add comment
                   

New Report Analyzes the Current and Future Potential of Cancer Vaccines

redorbit.com
May 29, 2008
        

Posted on: Thursday, 29 May 2008, 12:00 CDT Research and Markets (http://www.researchandmarkets.com/reports/c93083) has announced the addition of Cancer Vaccines: Aim and Shoot to their offering. This report aims to analyze the current and future potential of cancer vaccines by examining key...

add comment
                   

New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study (PR...

yahoo.com
May 28, 2008 6 related
        

Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc. today announced the publication of results from a pivotal phase 3 trial of RELISTOR subcutaneous injection in the May 29, 2008 issue of the New England Journal of Medicine.

add comment
                   

New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study

tmcnet.com
May 28, 2008 2 related
        

Attention Medical, Health And Business Editors Study Demonstrated Efficacy of RELISTOR for Use in Advanced-Illness Patients with Opioid-Induced Constipation COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., May 28 /CNW/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics...

add comment
                   

New drug eases severe constipation (Reuters)

yahoo.com
May 28, 2008 15 related
        

By Gene Emery 52 minutes ago BOSTON (Reuters) - The drug prucalopride, which Belgium-based Movetis NV plans to market in Europe under the brand name Resolor, could help many of the 11 million people in Europe and 25 million worldwide suffering from chronic constipation. Dr. Michael Camilleri of...

add comment

BUYINS.NET: (WYE) SqueezeTrigger Price is $43.778. There is $513,561,075.00 That Short Sellers...

tmcnet.com
May 28, 2008 3 related
        

BUYINS.NET / www.squeezetrigger.com is monitoring Wyeth (NYSE:WYE) in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. Wyeth (NYSE:WYE) Wyeth is engaged in the discovery, development, manufacture,...

add comment

Citi Maintains 'Hold' Rating on Progenics Pharmaceuticals (PGNX), Increases Price Target

pharmiweb.co.uk
May 27, 2008
        

Street Insider ... More News related to Analyst Comments Citi maintains a 'Hold' rating on Progenics Pharmaceuticals Inc (Nasdaq: PGNX), but increases price target from $13 to $17. Citi analyst says, "PGNX announced Relistor pricing of $40 per vial, or $280 for the 7 vial...

add comment

PROGENICS PHARMACEUTICALS INC EPS Estimated At -1.89: Current Recommendation is Neutral

pharmiweb.co.uk
May 26, 2008 2 related
        

Released : Monday, May 26, 2008 1:25 PM Company: PROGENICS PHARMACEUTICALS INC Report Headline: "Oral Form Shows Statistically Significant Activity" Report Date: May 22, 2008 Current FY EPS Estimate [FY2008]: -1.89 Previous EPS Estimate for Current FY [FY2008]: -1.89 Current Quarter EPS Estimate...

add comment